This website is intended for US healthcare professionals only.
VYEPTI permanent J-code (J3032) is now available. Learn more
Lundbeck is committed to providing information that may help patients and providers throughout the access and reimbursement process. Below are resources that may be helpful. Resources and access support are also available from a VYEPTI CONNECT Liaison or a Field Reimbursement Specialist.
Download the enrollment form and begin the benefits investigation process.
Download information about VYEPTI CONNECT. This optional program for patients and providers offers access support throughout the treatment journey.
Physicians who do not wish to enroll in VYEPTI CONNECT but still want access and reimbursement support from a Field Reimbursement Specialist should download and submit this form.
Providers in California who have prescribed VYEPTI must have their patients fill out this form and submit it along with the VYEPTI CONNECT Enrollment Form.
Information about the ordering and distribution of VYEPTI under the medical benefit.
Information that may be helpful when submitting claims for VYEPTI.
Information that can help you organize material that may be needed to complete a PA for VYEPTI.
Information about what may be needed to complete a Letter of Medical Necessity.
Information about what may be needed to complete a Letter of Appeal.
Information on eligibility requirements and how your commercial patients can enroll in the program.
Review the Terms and Conditions for VYEPTI CONNECT support.
Review the Terms and Conditions for the VYEPTI Copay Assistance Program.
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.
VYEPTI is indicated for the preventive treatment of migraine in adults.
Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Prescribing Information and Patient Information.
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.
VYEPTI is indicated for the preventive treatment of migraine in adults.
Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Prescribing Information and Patient Information.